Smartweave, Inc.
OperatingBiotech · Boston, MA
Personalized connective tissue treatments. For patients who deserve better than one-size-fits-all.
Financials
FY2023–FY2024 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps markedA dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Team
15 people
Co-Chief, Division of Urogynecology and Pelvic Reconstructive Surgery, Stanford Medicine. Recipient of multiple NIH and CIRM grants for regenerative medicine research.
Medical device executive with experience spanning early-stage startups to global leaders, including Stryker, Edwards, and Johnson & Johnson. UPR and Wharton alumni.
Advisor Professor of Urology and Obstetrics and Gynecology at Stanford University School of Medicine. Victor A. Politano Award recipient for outstanding achievement in urinary continence. Author of 100+ peer-reviewed articles.
Orthopedic surgeon specializing in complex joint replacement. Former HHMI-NIH Medical Research Scholar with a focus on bone growth factors.
Assistant Professor at Cedars-Sinai, Orthopedic Research Lab. Expert in regenerative medicine, particularly tendon regeneration. PhD in Tissue Engineering from the Hebrew University of Jerusalem, Israel.
Professor of Chemical Engineering at the University of Puerto Rico. Board member of the Cellular and Molecular Technologies Study Section at the NIH.
Cardiologist at Ascension St. Vincent, Chair of Ascension National Cardiovascular Service Line, Past President of the American College of Cardiology.
Show 6 more peopleShow fewer
Medical Director of Cardiothoracic Surgery at Baylor Scott & White Health, Vice Chair of the American Board of Thoracic Surgery, Cardiothoracic Surgeon.
Formerly Visiting Assistant Professor at Clark University. Expertise in Cellular and Regenerative Biology with grant and fellowship support from NSF and CIRM.
Regulatory compliance specialist for the life sciences and medical device industries.
Director of Grants and Enterprise Development at Smartweave Inc PhD in Molecular and Cellular Biology with a background in Regenerative Biology. Passionate about bringing personalized regenerative medicine to patients with connective tissue injuries.
Names and titles as disclosed on SEC Form C, WeFunder. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.